CR20160199A - Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 - Google Patents
Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40Info
- Publication number
- CR20160199A CR20160199A CR20160199A CR20160199A CR20160199A CR 20160199 A CR20160199 A CR 20160199A CR 20160199 A CR20160199 A CR 20160199A CR 20160199 A CR20160199 A CR 20160199A CR 20160199 A CR20160199 A CR 20160199A
- Authority
- CR
- Costa Rica
- Prior art keywords
- agonist
- combined therapy
- ang2 antibody
- antibody
- ang2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a la terapia combinada de un anticuerpo que se une a angiopoyetina humana 2 (ANG-2) con un agonista de CD40.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13198753 | 2013-12-20 | ||
| EP14158331 | 2014-03-07 | ||
| PCT/EP2014/078233 WO2015091655A1 (en) | 2013-12-20 | 2014-12-17 | Combination therapy with an anti-ang2 antibody and a cd40 agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20160199A true CR20160199A (es) | 2016-06-17 |
Family
ID=52278610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20160199A CR20160199A (es) | 2013-12-20 | 2016-04-23 | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20150232548A1 (es) |
| EP (1) | EP3082857B1 (es) |
| JP (1) | JP6345787B2 (es) |
| KR (1) | KR20160085888A (es) |
| CN (1) | CN105611944A (es) |
| AU (1) | AU2014368695A1 (es) |
| BR (1) | BR112016007112A2 (es) |
| CA (1) | CA2923591A1 (es) |
| CL (1) | CL2016001586A1 (es) |
| CR (1) | CR20160199A (es) |
| EA (1) | EA201600474A1 (es) |
| HK (1) | HK1221409A1 (es) |
| IL (1) | IL244454A0 (es) |
| MX (1) | MX2016008099A (es) |
| PE (1) | PE20160753A1 (es) |
| PH (1) | PH12016500482A1 (es) |
| SG (1) | SG11201604594SA (es) |
| TW (1) | TWI559931B (es) |
| WO (1) | WO2015091655A1 (es) |
| ZA (1) | ZA201601895B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| MX382549B (es) | 2014-08-12 | 2025-03-13 | Alligator Bioscience Ab | Combinación con anticuerpos anti-cd40 y anticuerpos anti-pd-1. |
| AU2015345320A1 (en) | 2014-11-10 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-IL-1beta antibodies and methods of use |
| BR112017009790A2 (pt) * | 2014-11-10 | 2017-12-19 | Hoffmann La Roche | anticorpos direcionados ao anti-ang2 e métodos de uso |
| JP2017537896A (ja) | 2014-11-10 | 2017-12-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重特異性抗体及び眼科に使用する方法 |
| CN107771184B (zh) | 2015-06-29 | 2022-11-01 | 百时美施贵宝公司 | 针对cd40的抗体 |
| BR112018013407A2 (en) | 2015-12-30 | 2018-12-18 | Kodiak Sciences Inc. | antibodies and conjugates thereof |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| KR20200091901A (ko) | 2017-12-01 | 2020-07-31 | 시애틀 지네틱스, 인크. | 암을 치료하기 위한 cd47 항체 및 이의 용도 |
| CN111788227B (zh) | 2017-12-27 | 2025-02-25 | 百时美施贵宝公司 | 抗cd40抗体及其用途 |
| SG11202008242XA (en) | 2018-03-02 | 2020-09-29 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| PE20211863A1 (es) * | 2018-10-01 | 2021-09-21 | Hoffmann La Roche | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap |
| SG11202108832XA (en) * | 2019-02-25 | 2021-09-29 | Pharmabcine Inc | Anti-ang2 antibody and use thereof |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| TWI877179B (zh) * | 2019-06-27 | 2025-03-21 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
| CN112168960A (zh) * | 2019-07-03 | 2021-01-05 | 义慧科技(深圳)有限公司 | 抗VEGF抗体和抗ANG2抗体在制备治疗具有Ras突变的肿瘤的药物中的应用 |
| EP4027998A1 (en) | 2019-09-09 | 2022-07-20 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2025178471A1 (ko) * | 2024-02-20 | 2025-08-28 | 주식회사 맵틱스 | Tie2 및 vegf에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8133979B2 (en) * | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
-
2014
- 2014-12-17 JP JP2016541193A patent/JP6345787B2/ja not_active Expired - Fee Related
- 2014-12-17 PE PE2016000675A patent/PE20160753A1/es unknown
- 2014-12-17 HK HK16109582.7A patent/HK1221409A1/zh unknown
- 2014-12-17 CN CN201480056156.XA patent/CN105611944A/zh active Pending
- 2014-12-17 MX MX2016008099A patent/MX2016008099A/es unknown
- 2014-12-17 WO PCT/EP2014/078233 patent/WO2015091655A1/en not_active Ceased
- 2014-12-17 AU AU2014368695A patent/AU2014368695A1/en not_active Abandoned
- 2014-12-17 KR KR1020167016096A patent/KR20160085888A/ko not_active Ceased
- 2014-12-17 BR BR112016007112A patent/BR112016007112A2/pt active Search and Examination
- 2014-12-17 EA EA201600474A patent/EA201600474A1/ru unknown
- 2014-12-17 CA CA2923591A patent/CA2923591A1/en not_active Abandoned
- 2014-12-17 EP EP14821592.4A patent/EP3082857B1/en not_active Not-in-force
- 2014-12-17 SG SG11201604594SA patent/SG11201604594SA/en unknown
- 2014-12-18 US US14/575,121 patent/US20150232548A1/en not_active Abandoned
- 2014-12-19 TW TW103144626A patent/TWI559931B/zh not_active IP Right Cessation
-
2016
- 2016-03-06 IL IL244454A patent/IL244454A0/en unknown
- 2016-03-11 PH PH12016500482A patent/PH12016500482A1/en unknown
- 2016-03-17 ZA ZA2016/01895A patent/ZA201601895B/en unknown
- 2016-04-23 CR CR20160199A patent/CR20160199A/es unknown
- 2016-06-17 CL CL2016001586A patent/CL2016001586A1/es unknown
-
2017
- 2017-10-06 US US15/726,873 patent/US20180134780A1/en not_active Abandoned
-
2020
- 2020-02-28 US US16/804,174 patent/US20200199215A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PH12016500482A1 (en) | 2016-05-16 |
| JP2017504600A (ja) | 2017-02-09 |
| TW201526915A (zh) | 2015-07-16 |
| AU2014368695A1 (en) | 2016-04-14 |
| CA2923591A1 (en) | 2015-06-25 |
| EA201600474A1 (ru) | 2016-11-30 |
| PE20160753A1 (es) | 2016-08-01 |
| CL2016001586A1 (es) | 2017-05-12 |
| WO2015091655A1 (en) | 2015-06-25 |
| ZA201601895B (en) | 2018-11-28 |
| IL244454A0 (en) | 2016-04-21 |
| EP3082857B1 (en) | 2018-07-25 |
| JP6345787B2 (ja) | 2018-06-20 |
| HK1221409A1 (zh) | 2017-06-02 |
| US20200199215A1 (en) | 2020-06-25 |
| CN105611944A (zh) | 2016-05-25 |
| BR112016007112A2 (pt) | 2017-09-19 |
| EP3082857A1 (en) | 2016-10-26 |
| TWI559931B (en) | 2016-12-01 |
| US20180134780A1 (en) | 2018-05-17 |
| SG11201604594SA (en) | 2016-07-28 |
| KR20160085888A (ko) | 2016-07-18 |
| MX2016008099A (es) | 2016-10-13 |
| US20150232548A1 (en) | 2015-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20160199A (es) | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 | |
| BR112016000903A2 (pt) | anticorpos | |
| DOP2018000181A (es) | Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina | |
| DOP2016000224A (es) | Tratamientos combinados con anticuerpos anti-cd38 | |
| PH12015501071A1 (en) | Combination therapy of anti-her3 antibodies | |
| CL2016000460A1 (es) | Proteínas de unión al antígeno gitr | |
| PH12015502565B1 (en) | Anti-transferrin receptor antibodies and methods of use | |
| MX2015014500A (es) | Terapia de combinacion de anticuerpos contra csf-1r y agonista de tlr9. | |
| IL244111A0 (en) | Survival benefit in patients with solid tumors with elevated c-reactive protein levels | |
| UY35399A (es) | Conjugados de fármacos con anticuerpos | |
| MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
| IN2014DN05885A (es) | ||
| CR20150247A (es) | Anticuerpos de antihemaglutinina y métodos de uso | |
| TWD165139S (zh) | 項鍊 | |
| PT2992016T (pt) | Terapia de combinação de um anticorpo anti-cd20 afucosilado com um conjugado anticorpo do cd79b-fármaco | |
| BR112015008117A2 (pt) | benzamidas | |
| TWD165504S (zh) | 錶 | |
| CO7151478A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 | |
| AR097668A1 (es) | Colorante-polímero | |
| CL2015002666A1 (es) | Formas de dosificación sólidas de antiemético de liberación prolongada | |
| PH12016501201A1 (en) | Synthesis of ent-progesterone and intermediates thereof | |
| TWD166471S (zh) | 手錶 | |
| BR112015023730A2 (pt) | uso de sedoeptulose como suplemento nutricional | |
| MX2015012902A (es) | Sintesis de ent-progesterona e intermediarios de la misma. | |
| AR098790A1 (es) | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 |